1. Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.
- Author
-
Chiaradonna, Ferdinando, Barozzi, Iros, Miccolo, Claudia, Bucci, Gabriele, Palorini, Roberta, Fornasari, Lorenzo, Botrugno, Oronza A., Pruneri, Giancarlo, Masullo, Michele, Passafaro, Alfonso, Galimberti, Viviana E., Fantin, Valeria R., Richon, Victoria M., Pece, Salvatore, Viale, Giuseppe, Di Fiore, Pier Paolo, Draetta, Giulio, Pelicci, Pier Giuseppe, Minucci, Saverio, and Chiocca, Susanna
- Subjects
- *
HYDROXAMIC acids , *BREAST cancer treatment , *HISTONE deacetylase inhibitors , *BREAST tumor treatment , *GENETICS of breast cancer , *CANCER cells , *GENE expression , *THERAPEUTICS - Abstract
Aims: Vorinostat (suberoylanilide hydroxamic acid; SAHA) is a histone deacetylase inhibitor (HDACi) approved in the clinics for the treatment of T-cell lymphoma and with the potential to be effective also in breast cancer. We investigated the responsiveness to SAHA in human breast primary tumors and cancer cell lines. Results: We observed a differential response to drug treatment in both human breast primary tumors and cancer cell lines. Gene expression analysis of the breast cancer cell lines revealed that genes involved in cell adhesion and redox pathways, especially glutathione metabolism, were differentially expressed in the cell lines resistant to SAHA compared with the sensitive ones, indicating their possible association with drug resistance mechanisms. Notably, such an association was also observed in breast primary tumors. Indeed, addition of buthionine sulfoximine (BSO), a compound capable of depleting cellular glutathione, significantly enhanced the cytotoxicity of SAHA in both breast cancer cell lines and primary breast tumors. Innovation: We identify and validate transcriptional differences in genes involved in redox pathways, which include potential predictive markers of sensitivity to SAHA. Conclusion: In breast cancer, it could be relevant to evaluate the expression of antioxidant genes that may favor tumor resistance as a factor to consider for potential clinical application and treatment with epigenetic drugs (HDACis). Antioxid. Redox Signal. 23, 15-29. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF